Login to Your Account

CTI, Novartis Enter Xyotax Deal; Option On Pixantrone

By Aaron Lorenzo

Tuesday, September 19, 2006
In a two-part arrangement, Cell Therapeutics Inc. agreed to partner Xyotax (poliglumex paclitaxel) with Novartis AG in a deal worth up to $285 million, and there's an option for another $111.5 million deal for pixantrone. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription